CAPRISA

AcronymDefinition
CAPRISACentre for the AIDS Programme of Research in South Africa
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Research institutes including CAPRISA that have established research clinics connected with hospitals that provide SRHS might be approached by patients requesting TOP information from clinic staff, while study participants who become pregnant during research studies conducted by Wits RHI may approach study clinicians requesting TOP-related information, and their questions cannot be answered unless certain criteria implemented by PLGHA are met.
(1) Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa
Salim Abdool Karim, head of the CAPRISA consortium and president of the Medical Research Council.
Dr Salim S Abdool Karim, Director of Centre for the AIDS Program of Research in South Africa (CAPRISA) said to Citizen News Service (CNS) at AIDS Vaccine 2012 in Boston, that CAPRISA-004 study had assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir for the prevention of HIV acquisition in women.
The Center for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of TDF for the prevention of HIV in women.
(CAPRISA), Study of Microbicide Gel Shows Reduced Risk of HIV and Herpes
At the XVIII International AIDS Conference in July 2010, the CAPRISA 004 study [3] reported encouraging findings for the use of a vaginal microbicide containing tenofovir.
New HIV prevention options such as Treatment for Prevention, CAPRISA gel - a female controlled microbicide, and iPreX - a pre-exposure prophylaxis - have emerged adding hope to people who want to protect themselves and their loved ones from the virus.
In the double-blind, randomized, and well-publicized CAPRISA (Centre for the AIDS Programme of Research in South Africa) 004 trial, a 1% vaginal gel formulation of tenofovir reduced HIV acquisition by approximately 39% overall and by 54% in women with high adherence to the protocol for gel application (Science 2010;329:1168-74).
The randomized, double-blind placebo-controlled Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial studied 889 sexually active African women (Science 2010;329:1168-74).
CAPRISA 004, the results of which were released at the 2010 International AIDS Conference in Vienna, found that a microbicide gel containing tenofovir was 39% effective in preventing HIV acquisition by African women.
Women who used the gel had a 51% reduction in new herpes infections, said Salim Abdool Karim, the director of the Centre for the AIDS Programme of Research in South Africa, or Caprisa, which coordinated the study.